News | Computer-Aided Detection Software | June 01, 2018

FDA Proposes to Reclassify Some Types of Radiology Image Software Analyzers

Proposed order would reduce regulatory approval burden for various computer-aided detection devices

FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers

June 1, 2018 — The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical image analyzers, or computer-aided detection (CAD) devices, from class III to class II devices. This includes CAD devices for mammography breast cancer, ultrasound breast lesions and radiograph lung nodules.

If finalized, this proposed order will reclassify CAD devices for certain radiological applications from Class III devices requiring premarket approval, to Class II devices, requiring a less burdensome premarket notification (510(k)) with special controls. This will reduce the regulatory burden on the medical device industry, streamline review for these types of devices, and provide more timely access to these devices for patients.

The agency is proposing special controls that, in addition to general controls, will provide a reasonable assurance of safety and effectiveness.

This proposed order is part of the Center for Devices and Radiological Health’s goal to strike the right balance between premarket and postmarket data collection. This proposed order also promotes innovation in diagnostic imaging, according to the FDA, through a more consistent and streamlined approach to review many types of radiological computer aided-detection, diagnosis and triage software under the 510(k) pathway. Streamlined premarket review will provide for more timely access to these types of devices for patients, while still maintaining the highest standards of safety and effectiveness.

The agency said it welcomes comments regarding this proposed order. The comment period will be open for 60 days.

Questions about this proposed order can be directed to CDRH’s Division of Industry and Consumer Education (DICE) at [email protected], or via phone at 1-800-638-2041, or (301) 796-7100.

For more information: www.fda.gov

Related Content

Nuance Launches Cloud-Based mPower Clinical Analytics Platform at AHRA 2018
Technology | Analytics Software | August 16, 2018
At the Association for Medical Imaging Management (AHRA) 2018 Annual Meeting and Exposition, July 22-25 in Orlando, Fla...
Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Intel and Philips Demonstrate CPU Ability in Deep Learning Inference Test Cases
News | Artificial Intelligence | August 15, 2018
Intel and Philips recently tested two healthcare uses for deep learning inference models using Intel Xeon Scalable...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
CMS Proposes Overhaul of Medicare's Accountable Care Organization Program
News | Radiology Business | August 09, 2018
The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule August 9 that would overhaul the Medicare...
Visage Signs Mercy for Visage 7 Open Archive
News | Enterprise Imaging | August 09, 2018
Visage Imaging Inc. announced that it has signed a seven-year contract with Mercy, the fifth largest Catholic health...
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Aidoc Receives FDA Clearance for AI Detection of Acute Intracranial Hemorrhage
Technology | Clinical Decision Support | August 08, 2018
Aidoc announced that it was granted U.S. Food and Drug Administration (FDA) clearance for the first product of its...
Overlay Init